Moderna seeks China market access amid US-China tensions

Moderna Inc. is actively exploring collaboration opportunities in China, signaling the American biotechnology firm's determination to access one of the world's largest pharmaceutical markets even as US-China relations remain strained.

The Cambridge-based messenger RNA vaccine developer has indicated willingness to establish partnerships with Chinese entities to expand its presence in the region. Such moves reflect the broader pharmaceutical sector's pragmatic approach to commercial expansion, balancing business imperatives against geopolitical headwinds.

China represents a significant growth opportunity for Western vaccine manufacturers, with a population exceeding 1.4 billion and rising demand for advanced immunological treatments. Despite trade tensions and regulatory scrutiny affecting US-China relations, major pharmaceutical companies have continued exploring market entry strategies in the country.

Moderna's outreach to Chinese partners comes as the company seeks to diversify its revenue streams beyond developed Western markets. The pharmaceutical industry has historically maintained that scientific cooperation and commercial partnerships transcend political tensions, though regulatory approvals and market access remain subject to governmental oversight in both countries.

The company's strategy reflects a calculated assessment that long-term commercial interests in the Chinese market justify engagement despite current geopolitical uncertainties affecting US-Asia relations.